Scholars Central

ArticlePublished 3 May 2019

Design, synthesis and biological evaluation of newer HDAC inhibitors as anticancer agents

Authors: Aparna V. Chavan, S.S. Mahajan

Der Pharma Chemica

Volume 7 · Issue 7 · Pages 199–204

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Inhibition of histone deacetylase (HDAC) enzymes is emerging as an innovative and effective approach for the treatment of cancer. Hundreds of hydroxamic acid derivatives were designed and tested in silico for their interaction with histone deacetylase (HDAC) enzyme. A series of semi/thiocarbazone hydroxamic acid derivatives with moderate to good G-score were designed, synthesized and evaluated for their ability to inhibit cell proliferation in cancer cell lines. Many compounds showed encouraging anti-proliferative activity against the cancer cell lines, MCF-7, HCT-15 & Jurkat. Compounds C4 & C10 showed promising activity against all the three cell lines, while compound C6 and C12 showed colon cancer cell specific inhibition.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Der Pharma Chemica.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalDer Pharma Chemica
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Aparna V. Chavan”
  • BylineArticles whose byline prints “S.S. Mahajan”